Zydus Lifesciences Limited announced a significant regulatory milestone as its innovative drug Desidustat tablets received approval from China's National Medical Products Administration (NMPA) for treating renal anaemia. Following the approval, the company has confirmed the licensing arrangement with China Medical System Holdings Limited, representing a breakthrough in addressing the substantial unmet medical needs for Chronic Kidney Disease patients in China.

Drug Approval and Licensing Partnership

The NMPA approval covers Desidustat tablets for renal anaemia treatment in China, marking a crucial regulatory achievement for the innovative therapy. CMS International Development and Management Limited, a wholly-owned subsidiary of China Medical System Holdings Limited, obtained an exclusive license for the drug from Zydus in 2020. The licensing arrangement has now been activated following the regulatory approval.

Clinical Innovation and Mechanism

Desidustat tablets represent a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) specifically designed for treating anaemia in Chronic Kidney Disease patients. The drug addresses a critical medical challenge where impaired kidneys reduce Erythropoietin production, leading to anaemia development. HIF-PHI promotes erythropoiesis by increasing endogenous erythropoietin and reducing hepcidin, thereby improving iron availability.

The China Phase III clinical trial demonstrated positive results, meeting its primary efficacy endpoint. Extension study results showed the drug could maintain haemoglobin levels within target ranges over long-term treatment with acceptable safety profiles, while significantly reducing hepcidin levels and improving iron metabolism disorders.

Market Opportunity and Patient Impact

China presents a substantial market opportunity with significant unmet medical needs in CKD anaemia treatment. The oral administration of Desidustat is expected to improve patient treatment compliance and address critical gaps in current therapy options.

Indian Market Success

Desidustat is discovered, developed and marketed by Zydus in India under the brand name Oxemia™. The drug has demonstrated significant clinical success, with more than 1 lakh CKD patients in India successfully treated since its launch in 2022.

Management Commentary

Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Limited, commented on the development: "We are encouraged by the NMPA's approval for marketing the drug in China. Our life-changing discoveries are driven by a commitment to improving patient outcomes and enabling healthier, more fulfilled lives, globally. We are happy to partner with CMS and are confident that this will expand access to patients suffering from Chronic Kidney Disease across Greater China."

The approval represents a significant milestone in Zydus' mission to transform lives through pathbreaking discoveries and expand access to innovative healthcare solutions globally. With CMS's proven commercialization capabilities and extensive networks in specialty therapeutic fields, the partnership positions Desidustat for successful market penetration across Greater China.

Zydus Lifesciences has achieved a significant regulatory milestone with the receipt of final approval from the United States Food and Drug Administration (USFDA) for its Cevimeline Hydrochloride Capsules 30mg. This approval marks an important expansion of the company's pharmaceutical offerings in the competitive US market.

Product Details and Therapeutic Application

The approved medication is specifically indicated for treating dry mouth (xerostomia) associated with Sjögren's syndrome. Sjögren's syndrome is an autoimmune disorder that primarily affects the body's moisture-producing glands, leading to symptoms such as dry mouth and dry eyes. Cevimeline is a muscarinic receptor agonist that stimulates salivary secretion.

Manufacturing and Market Opportunity

The company projects annual sales of USD 26.9 million for this product based on IQVIA MAT data, indicating substantial market potential in the treatment of Sjögren's syndrome-related symptoms. The Cevimeline Hydrochloride Capsules 30mg will be manufactured at Zydus Lifesciences 's SEZ-II facility in Ahmedabad.

Regulatory Portfolio Expansion

This latest approval strengthens Zydus Lifesciences' regulatory portfolio in the United States market. The company now holds 436 approvals and has filed 505 ANDAs since commencing the filing process in FY 2003-04. The final approval status allows the company to commence commercial activities for this product in the United States market, contributing to its revenue diversification strategy.

Strategic Significance

The USFDA approval represents a valuable addition to Zydus Lifesciences' pharmaceutical portfolio, particularly in the niche market of treatments for autoimmune-related complications. This approval enhances the company's presence in specialized therapeutic segments addressing conditions that affect moisture-producing glands.